Printer Friendly

AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.

Tokyo, Japan, June 7, 2006 - (JCN) - AnGes MG announced on June 5 its future strategies for the development of AMG0001, HGF (Hepatocyte Growth Factor) gene medicine.

Specifically, the company will reinforce its current partnership with Daiichi Pharmaceutical. Further, AnGes MG has decided to place the highest priority on development in the field of peripheral arterial disease in Japan.

Regarding overseas development, AnGes MG will proceed with research in both peripheral arterial disease (PAD) and ischemic heart disease (IHD).

Currently, AnGes MG and Daiichi Pharmaceutical are jointly undertaking phase II and III clinical trials for PAD overseas and in Japan, respectively, and phase I and pre-clinical trials for IHD overseas and in Japan, respectively.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 8, 2006
Words:123
Previous Article:AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.
Next Article:Lion, Ota Sleep Center Elucidate that Tomato Vinegar Helps Improve Sleep Quality.


Related Articles
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Patents HVJ Envelope Vector in US.
AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.
BIOLEX WILL USE LEX TO CREATE LINE FOR KRINGLE NK4.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Announces Results of Phase II Clinical Trials of HGF Gene Medicine.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters